

Hsien-Yuan Lane

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8216426/hsien-yuan-lane-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

2,513
citations

25
h-index

49
g-index

84
ext. papers

3,191
ext. citations

4.8
avg. IF

5.7
L-index

#	Paper	IF	Citations
79	Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial.. <i>International Journal of Neuropsychopharmacology</i> , 2022 ,	5.8	1
78	Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms.. <i>Pharmacology Biochemistry and Behavior</i> , 2022 , 173335	3.9	1
77	Suicide Ideation among Outpatients with Alcohol Use Disorder.. <i>Behavioural Neurology</i> , 2022 , 2022, 4138629		1
76	Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment. <i>Journal of Personalized Medicine</i> , 2022 , 12, 835	3.6	
75	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study. <i>Antioxidants</i> , 2021 , 10,	7.1	4
74	Efficiency of an Online Health-Promotion Program in Individuals with At-Risk Mental State during the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
73	d-Amino Acids and pLG72 in Alzheimer's Disease and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
72	Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 577-588	3.4	2
71	Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	18
70	Risk Assessment for Heroin Use and Craving Score Using Polygenic Risk Score. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
69	Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e216156	10.4	10
68	In Reply: Trough Melatonin Levels Have No Physiological or Clinical Relevance. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 393	3.4	
67	Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection. <i>Scientific Reports</i> , 2021 , 11, 10179	4.9	3
66	Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry. <i>Molecules</i> , 2021 , 26,	4.8	1
65	Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
64	An Investigation into Smartphone Addiction with Personality and Sleep Quality among University Students. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	6
63	Molecular Basis of Late-Life Depression. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4

62	Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 392-399	5.8	8
61	Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 135-144	3.4	5
60	Effects of the Health-Awareness-Strengthening Lifestyle Program in a Randomized Trial of Young Adults with an At-Risk Mental State. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
59	Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches. <i>Journal of Psychopharmacology</i> , 2021 , 35, 265-272	4.6	7
58	Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
57	Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
56	Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions. <i>Scientific Reports</i> , 2021 , 11, 6922	4.9	3
55	Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
54	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 423-433	3.4	2
53	From Menopause to Neurodegeneration-Molecular Basis and Potential Therapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
52	Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
51	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
50	An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020 , 8, 569	5.8	16
49	Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. <i>Journal of Psychopharmacology</i> , 2020 , 34, 495-505	4.6	11
48	Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD). <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 509-518	3.1	11
47	Genetic Effects and on Visual Learning of Patients with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 771-780	3.1	2
46	d-glutamate and Gut Microbiota in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	32
45	Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. <i>Current Drug Targets</i> , 2020 , 21, 610-615	3	10

44	Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	32
43	Benzoate treatment for adolescent anti-NMDAR encephalitis. <i>Schizophrenia Research</i> , 2020 , 222, 472-473	3.6	1
42	Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular Design, Dimensionality Reduction, and Peptide and Protein Design. <i>Molecules</i> , 2020 , 25,	4.8	23
41	pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase. <i>Scientific Reports</i> , 2019 , 9, 13221	4.9	9
40	C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2621-2627	3.1	3
39	The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019 , 10, 540	5.6	15
38	Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1030-1033	4.6	11
37	Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning: A case series. <i>Psychiatry and Clinical Neurosciences</i> , 2019 , 73, 348	6.2	1
36	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. <i>Frontiers in Psychiatry</i> , 2019 , 10, 93	5	28
35	Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. <i>Journal of Psychopharmacology</i> , 2019 , 33, 436-448	4.6	23
34	D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. <i>Pharmacology Biochemistry and Behavior</i> , 2019 , 185, 172760	3.9	26
33	Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2019 , 245, 1119-1125	6.6	14
32	Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2018 , 84, 422-432	7.9	65
31	Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. <i>Frontiers in Psychiatry</i> , 2018 , 9, 91	5	28
30	Brain Stimulation in Alzheimer's Disease. <i>Frontiers in Psychiatry</i> , 2018 , 9, 201	5	58
29	Combination of Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches. <i>Frontiers in Psychiatry</i> , 2018 , 9, 566	5	21
28	Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 357-368	3.8	53
27	Machine learning and systems genomics approaches for multi-omics data. <i>Biomarker Research</i> , 2017 , 5, 2	8	99

26	Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. <i>Scientific Reports</i> , 2017 , 7, 14849	4.9	48
25	Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms. <i>Journal of Agricultural and Food Chemistry</i> , 2017 , 65, 10792-10803 ⁵⁻⁷	5.7	23
24	Genetic Biomarkers on Age-Related Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2017 , 8, 247	5	23
23	Decreased mRNA expression for the two subunits of system xc(-), SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. <i>Journal of Psychiatric Research</i> , 2016 , 72, 58-63	5.2	36
22	Genome-wide association studies in pharmacogenomics of antidepressants. <i>Pharmacogenomics</i> , 2015 , 16, 555-66	2.6	30
21	Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. <i>Biological Psychiatry</i> , 2014 , 75, 678-85	7.9	80
20	Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. <i>Molecular Psychiatry</i> , 2014 , 19, 636-7	15.1	27
19	NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5169-79	3.3	44
18	NMDA pathology and treatment of schizophrenia. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5118-26	3.3	14
17	Evaluation of psychometric properties of the Chinese Mandarin version State-Trait Anxiety Inventory Y form in Taiwanese outpatients with anxiety disorders. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2013 , 20, 499-507	2.4	23
16	The C-terminal region of G72 increases D-amino acid oxidase activity. <i>International Journal of Molecular Sciences</i> , 2013 , 15, 29-43	6.3	20
15	Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. <i>JAMA Psychiatry</i> , 2013 , 70, 1267-75	14.5	144
14	Glutamate signaling in the pathophysiology and therapy of schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , 2012 , 100, 665-77	3.9	106
13	Assessing gene-gene interactions in pharmacogenomics. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 15-27.5	4.5	46
12	Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 527-33	2.7	22
11	NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2012 , 10, 272-85	7.6	55
10	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 451-60	5.8	128
9	Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. <i>Biological Psychology</i> , 2010 , 83, 79-83	3.2	23

8	Sensitivity and specificity of the Chinese version of the Schizotypal Personality Questionnaire-Brief for identifying undergraduate students susceptible to psychosis. <i>International Journal of Nursing Studies</i> , 2010 , 47, 1535-44	5.8	14
7	Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. <i>Biological Psychiatry</i> , 2008 , 63, 9-12	7.9	132
6	A model testing factors that influence physical activity for Taiwanese adults with anxiety. <i>Research in Nursing and Health</i> , 2008 , 31, 476-89	2	11
5	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 2006 , 60, 645-9	7.9	148
4	Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. <i>Archives of General Psychiatry</i> , 2005 , 62, 1196-204		227
3	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 2004 , 55, 452-6	7.9	282
2	Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 4-10	1.7	14
1	Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1998 , 22, 723-39	5.5	68